[{"id":"79725e7c-a938-4a9e-b556-bf960936b158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03618641","created_at":"2021-09-17T01:53:43.496Z","updated_at":"2025-02-25T16:31:32.025Z","phase":"Phase 2","brief_title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","source_id_and_acronym":"NCT03618641","lead_sponsor":"Diwakar Davar","biomarkers":" CD8 • CD4 • SOX10","pipe":"","alterations":" ","tags":["CD8 • CD4 • SOX10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/08/2018","start_date":" 08/08/2018","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-07"},{"id":"93546d33-d260-437a-9cd5-b7629d9d588d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708418","created_at":"2023-04-01T19:06:08.459Z","updated_at":"2025-02-25T16:38:10.265Z","phase":"Phase 2","brief_title":"A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma","source_id_and_acronym":"NCT04708418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"e0dcb469-2253-48cc-bf9a-3c24a50a8266","acronym":"","url":"https://clinicaltrials.gov/study/NCT04401995","created_at":"2022-04-05T20:52:55.878Z","updated_at":"2024-07-02T16:35:06.245Z","phase":"Phase 2","brief_title":"Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab","source_id_and_acronym":"NCT04401995","lead_sponsor":"Diwakar Davar","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 07/30/2028","primary_completion_date":" 07/30/2028","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2024-05-03"},{"id":"c7d821cf-1074-4b09-aa9f-2289017bf8ff","acronym":"CMP-001-007","url":"https://clinicaltrials.gov/study/NCT04633278","created_at":"2021-01-19T20:36:57.016Z","updated_at":"2024-07-02T16:35:21.076Z","phase":"Phase 2","brief_title":"CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04633278 - CMP-001-007","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 01/19/2024","primary_completion_date":" 01/19/2024","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2024-02-02"},{"id":"e5a8e0c7-3d27-4fa1-bebf-518326e168c8","acronym":"CMP-001-003","url":"https://clinicaltrials.gov/study/NCT03438318","created_at":"2021-01-18T16:56:58.252Z","updated_at":"2024-07-02T16:36:06.118Z","phase":"Phase 1b","brief_title":"Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03438318 - CMP-001-003","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • vidutolimod (CMP-001) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 12/11/2019","primary_completion_date":" 12/11/2019","study_txt":" Completion: 12/11/2019","study_completion_date":" 12/11/2019","last_update_posted":"2022-08-03"},{"id":"5bd424f1-c902-443d-b96a-53719bab44f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04807192","created_at":"2021-03-19T15:59:09.329Z","updated_at":"2024-07-02T16:36:28.123Z","phase":"Phase 2","brief_title":"CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT04807192","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vidutolimod (CMP-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2021-07-09"}]